Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;24(11):4495-502.
doi: 10.1007/s00520-016-3287-y. Epub 2016 May 28.

Cancer Cachexia, Sarcopenia and Biochemical Markers in Patients With Advanced Non-Small Cell Lung Cancer-Chemotherapy Toxicity and Prognostic Value


Cancer Cachexia, Sarcopenia and Biochemical Markers in Patients With Advanced Non-Small Cell Lung Cancer-Chemotherapy Toxicity and Prognostic Value

Drazena Srdic et al. Support Care Cancer. .


Purpose: Cancer cachexia and sarcopenia are frequently observed in cancer patients and associated with poor survival. The majority of studies of cancer cachexia and sarcopenia have been done in patients with solid tumors of different origins, and there are currently no good predictors of the benefit of chemotherapy or factors that predict survival in advanced cancer. The purpose of our prospective study was to evaluate prevalence of cachexia and sarcopenia using international consensus definition and criteria for diagnosis in patients with diagnosed advanced non-small cell lung cancer (NSCLC) stage IIIB and IV and their relation to chemotherapy toxicity and survival prediction. A secondary aim was to compare several biochemical markers (CRP, IL-6, protein, and albumin) with time to tumor progression in order to assess prognostic value or to guide a treatment.

Methods: Between December 2013 and April 2015, the prospective cohort study of 100 Caucasian patients with advanced NSCLC stage IIIB or IV, who were referred consecutively to Department for Respiratory Diseases "Jordanovac," was evaluated. Anthropometric measurements and biochemical data (CRP, albumin, protein, IL-6, haemoglobin) together with body composition measurements (total muscle cross-sectional area, lumbar skeletal muscle index) were obtained for each patient before starting with platinum-doublet therapy. Skeletal muscle cross-sectional area at the third lumbar vertebra was measured by computerized tomography, and sarcopenia was defined using a previously published cutoff point. Toxicity was assessed after cycle 1 of treatment and time-to-tumor progression was determined prospectively.

Results: One hundred patients with advanced lung cancer were recruited: 67 were male and median age was 64 years. The median time to disease progression was 187 days. The prevalence of cachexia and sarcopenia in study cohort was 69 and 47 %, respectively. CRP, IL-6, and albumin concentration in cachectic compared to non-cachectic patients demonstrated statistically significant difference (p = 0.020, p = 0.040, p = 0.003). Cachexia and sarcopenia were not found to be predictors of chemotoxicity nor was time to tumor progression. On the contrary, albumin concentration with established cutoff point of 37.5 g/L was clearly proved as the predictive factor of both chemotoxicity (OR (95 % CI) = 0.85; p < 0.001) and survival (HR (95 % CI) = 0.55).

Conclusions: Albumin level has been shown to be more important predictive marker of chemotherapy toxicity and survival than cachexia and sarcopenia are. This approach in clinical settings can be used to guide the choice of oncologic treatment.

Keywords: Cancer cachexia; Chemotherapy toxicity; Non-small cell lung cancer; Sarcopenia.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles


    1. J Thorac Oncol. 2015 Dec;10 (12 ):1795-9 - PubMed
    1. Am J Med. 1980 Oct;69(4):491-7 - PubMed
    1. J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):1-5 - PubMed
    1. Curr Opin Clin Nutr Metab Care. 2005 May;8(3):265-9 - PubMed
    1. PLoS One. 2012;7(5):e37563 - PubMed